Association among metabolic syndrome, inflammation, and survival in prostate cancer
- 1 May 2018
- journal article
- research article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 36 (5) , 240.e1-240.e11
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Metabolic Syndrome as a Peculiar Target for Management of Prostate Cancer PatientsClinical Genitourinary Cancer, 2013
- The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: An unresolved controversyCritical Reviews in Oncology/Hematology, 2013
- A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapyBJU International, 2011
- Body Mass Index, Prostate Cancer–Specific Mortality, and Biochemical Recurrence: a Systematic Review and Meta-analysisCancer Prevention Research, 2011
- Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancerAnnals of Oncology, 2010
- B-cell-derived lymphotoxin promotes castration-resistant prostate cancerNature, 2010
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate CancerJNCI: Journal of the National Cancer Institute, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysisThe Lancet Oncology, 2008
- Inflammation in prostate carcinogenesisNature Reviews Cancer, 2007